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Abstract
While the Cu(II) binding sites of the prion protein have been well studied under Cu-saturation
conditions, the identity of the residues involved in coordinating Cu(II) at low stoichiometries and
the order in which the binding sites load with Cu(II), remain unresolved. In this study, we have used
two mass spectrometry based methods to gather insight into Cu(II)-prion binding under different
stoichiometric loadings of Cu(II). The first method uses metal-catalyzed oxidation reactions to site
specifically modify the residues bound to Cu(II) in solution, and the second method determines Cu
binding sites based on the protection of His from modification by diethyl pyrocarbonate when this
residue binds Cu(II) in solution. For both methods, the residues that are labeled by these reactions
can then be unambiguously identified using tandem mass spectrometry. Upon applying these two
complementary methods to a construct of the prion protein that contains residues 23-28 and 57-98,
several noteworthy observations are made. Coordination of Cu(II) by multiple His imidazoles is
found at 1:1 and 1:2 PrP:Cu(II) ratios. Notably, there appear to be four to seven isomers of this
multiple histidine coordination mode in the 1:1 complex. Furthermore, our data clearly show that
His96 is the dominant Cu(II) binding ligand, as in every isomer His96 is bound to Cu(II). The
individual octarepeat binding sites begin to fill at ratios of 1:3 PrP:Cu(II) with no clear preference
for the order in which they load with Cu(II), although the His77 octarepeat appears to saturate last.
The existence of several ‘degenerate’ Cu binding modes at low PrP:Cu(II) ratios may allow it to
more readily accept additional Cu(II) ions, thus allowing PrP to transition from a singly Cu(II) bound
state to a multiply Cu(II) bound state as a function of cellular Cu(II) concentration.
The normal cellular form of the prion protein, denoted PrPC, is expressed in the central nervous
systems of mammals and avian species (1,2). The precise physiological function of PrP is not
known, although its role in neurodegenerative diseases, specifically the transmissible
spongiform encephalopathies, has been unequivocally established (1,3). Most hypotheses as
to the normal, cellular function of PrP focus on the fact that it is capable of binding divalent
copper with moderate to high affinity (4-9). There is also growing evidence that PrP may
interact with zinc (10). Cellular studies show that both copper and zinc induce endocytosis of
PrP, thus linking metal binding to a physiological response (5,11).
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Given PrP’s connection to these two metals, significant efforts have been made to characterize
the metal binding. Most progress has been made on characterizing PrP’s Cu(II)-binding modes
(7,12-15), whereas to our knowledge, few molecular details on the zinc binding coordination
sphere(s) have been published (16). The metal binding domain of PrP resides in the flexible
N-terminal domain, spanning residues 60-96 (human sequence) and has been shown to bind
approximately five Cu(II) ions (12,17,18) (Figure 1). This region contains four repeats of the
highly conserved octapeptide PHGGGWGW sequence (residues 60-91) followed by GTH
(residues 94-96). Recent studies also indicate that another binding site centered on His111
exists (14,15,19). When fully Cu(II)-saturated, the HGGGW segment of each octarepeat
coordinates a Cu(II) ion using a single histidine (His) imidazole, two deprotonated glycine
(Gly) amides, and a glycine carbonyl oxygen (7). The tryptophan (Trp) indole ring is held in
close proximity to the Cu(II) center, possibly via a hydrogen bonding interaction to an axially
bound water molecule. The GTH sequence, often referred to as the ‘fifth binding site’,
coordinates Cu(II) using deprotonated amide nitrogens from the Gly, Thr and His residues as
well as the imidazole ring of His (12).
Although the coordination spheres for the Cu(II) binding sites populated under Cu(II)-
saturation conditions are known with precise atomic detail, there is controversy over the Cu
(II) coordination modes populated at intermediate and low Cu(II) occupancies. Both
Chattopadhyay et al. and Wells et al. find evidence for a coordination mode involving multiple
histidine imidazole groups at low Cu(II) occupancy (13,14,19). In contrast, Klewpatinond et
al. find that Cu(II) ions are initially bound by sites located at His96 and His111 before the
HGGGW segments of the octarepeat region begin binding (15). Some of these discrepancies
may arise due to the fact that these researchers use different models systems, conditions and
techniques.
In this study, the copper binding sites of PrP(23-28, 57-98) at different stoichiometric loadings
of Cu(II) were examined using two mass spectrometry (MS)-based methods. The region
spanning residues 57-98 contains the histidine-centered Cu(II) binding sites identified by
studies on the full prion protein (20,21). The goals are to identify the residues involved in
coordinating Cu(II) at low stoichiometries and to determine the order in which the binding sites
load with Cu(II). The MS-based methods have two notable advantages over the spectroscopic
methods, such as EPR or CD, previously used to study the Cu(II) binding of prion protein
fragments. The MS-based methods can identify the specific amino acids bound to Cu(II)
without having to resort to isotopic labeling, and the presence of multiple Cu-protein isoforms
can become apparent. The first MS-based method was recently developed in our group and is
based on metal catalyzed oxidation (MCO) reactions and MS (22-26). We have demonstrated
that the MCO/MS method can identify the metal binding residues of peptides and proteins.
The method relies on the generation of reactive oxygen species at a redox-active metal center
such as Cu that then oxidize nearby amino acids in a given peptide or protein (Scheme 1). If
the appropriate reaction conditions are chosen, oxidation is limited to the side chains of the
amino acids bound to the metal. The oxidatively modified sites are then identified using tandem
MS (MS/MS). A second complementary technique is a covalent labeling method that relies on
diethyl pyrocarbonate (DEPC) to modify histidine residues and MS to identify these modified
sites. Reactions with DEPC can be used to identify Cu(II) binding sites because histidine’s
reactivity with DEPC is significantly decreased when this residue is bound to Cu (20,27). Qin
et al. applied a similar approach to probe metal binding sites in the PrP(23-231) protein using
a 10-fold molar excess of Cu(II) (20). The present work differs in two respects: (1) we have
used DEPC to probe metal binding under different stoichiometric loadings of Cu(II), and (2)
confidence in the assigned Cu(II) binding sites by this approach is greater because we have
used electron transfer dissociation (ETD) MS/MS to determine the extent to which individual
His residues are bound at different Cu(II) stoichiometries. ETD has been found to be less
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sensitive to side-chain modifications and often provides better sequence information for
modified peptides than collision-induced dissociation (CID) (28,29).
In accordance with previous work, we find evidence for coordination of Cu(II) by multiple His
imidazoles at low PrP:Cu(II) ratios (13,14,19). Most notably, there appear to be several possible
isomers of this multiple histidine coordination mode, four to seven by our current estimations.
Our data clearly show that His96 is the dominant Cu(II) binding ligand, as in every isomer
His96 is bound to Cu(II). Further, Cu(II)’s preference for His residues follows: His96 > His61
~ His 69 > His77 ~ His85. The individual octarepeat binding sites begin to fill at ratios of 1:3
PrP:Cu(II) with no clear preference for the order in which they load with Cu(II), although the
His77 octarepeat appears to saturate last.
MATERIAL AND METHODS
Peptide Synthesis
All peptides (Table 1) were prepared by solid-phase synthesis on an automated PS3 synthesizer
(Protein Technologies, Inc.) using standard fluorenylmethoxycarbonyl (Fmoc) methods.
Protected amino acids and coupling reagents were purchased from Protein Technologies, Inc.
(Tucson, AZ). The peptides were acetylated at the N-terminus and amidated at the C-terminus.
Peptides were cleaved from a Rink Amide MBHA resin, obtained from Novabiochem
(Gibbstown, NJ), over a 2 hour period using 95% trifluoroacetic acid/ 2.5% water/ 2.5%
triisopropylsilane solution (v/v/v). Finally, all peptides were purified by reverse-phase HPLC,
using a C18 column, and characterized by electrospray ionization mass spectrometry (ESI-
MS) on a Micromass Q-ToF micro.
Materials
Hydrogen peroxide (30%), formic acid, tris(hydroxymethyl)-aminomethane (Tris), and tris
(hydroxymethyl)aminomethane hydrochloride (Tris-HCl) were obtained from EM Science
(Gladstone, NJ). Diethyl pyrocarbonate (DEPC), imidazole, sodium ascorbate, ascorbic acid,
copper(II) sulfate, and ammonium acetate were purchased from the Sigma-Aldrich Corporation
(St. Louis, MO). Acetic acid and HPLC-grade methanol were obtained from Fisher Scientific
(Fair Lawn, NJ). Centricon molecular weight cutoff (MWCO) filters were obtained from
Millipore (Burlington, MA). All reagents were used as provided. Distilled, deionized water
was generated with a Millipore (Burlington, MA) Simplicity 185 water purification system.
Metal Catalyzed Oxidation (MCO) Reactions
Metal catalyzed oxidation reactions of all the peptides were performed at least three times at
room temperature in aqueous solutions containing 100 M peptide, 100-500 M CuSO4, 10
mM ascorbate, 2 mM H2O2, and 50 mM Tris-HCl/Tris, buffered to a pH of 7.4. Control
reactions were performed by incubating peptides with ascorbate and oxidant in the absence of
any metal ions. In all cases the reactions were initiated by the addition of ascorbate, H2O2, or
both. Reactions were stopped after 30 minutes by the addition of 1% (by volume) of glacial
acetic acid. Samples of PrP(23-28, 57-98) were then immediately desalted using 3,000 Da
molecular weight Centricon filters (Millipore, Bedford, MA) and frozen until ready for further
analysis. The other peptide samples were immediately frozen until ready for further analysis.
Diethyl Pyrocarbonate (DEPC) Modification Reactions
DEPC modification reactions of all the peptides were performed at least three times in 50 mM
ammonium acetate buffer solutions (pH 7.4) containing 100 M peptide and 100-500 M
CuSO4. Before reaction with DEPC, the Cu-peptide complexes were incubated for 30 min to
ensure complex formation. Samples were then reacted with 5-fold excess DEPC for 5 min.
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Control experiments were performed under the same conditions without CuSO4. In all cases
reactions were stopped by the addition of 10 % (by volume) of a 1.0 M imidazole solution,
which effectively acts to quench any further reactions of DEPC. Samples of PrP(23-28, 57-98)
were then immediately desalted using 3,000 Da molecular weight Centricon filters (Millipore,
Bedford, MA) and frozen until ready for further analysis. The other peptide samples were
immediately frozen until ready for further analysis.
Instrumentation
Mass spectral analyses were performed on either a Bruker (Billerica, MA) Esquire LC
quadrupole ion trap mass spectrometer or a Bruker HCTultra PTM Discovery system
quadrupole ion trap mass spectrometer. On both mass spectrometers the source conditions were
chosen to maximize the ion signal of the desired ions. For direct injection experiments on the
Esquire LC, the sample was delivered at 1 μL/min using a syringe pump. HPLC-MS analyses
on this mass spectrometer were conducted using an HP1100 (Agilent, Wilmington DE) system
with a Discovery C18 column (2.1 × 150 mm; Supelco). The LC effluent was split in a 1:4
ratio with the smaller outlet being fed into the electrospray ionization (ESI) source of the
quadrupole ion trap mass spectrometer. For separation of the oxidized isomers of some
peptides, a binary gradient was used. The two mobile phases that were used were (A) water
with 0.1% formic acid and (B) methanol with 0.1% formic acid. During the separation of the
oxidized isomers, the percentage increases of mobile phase B were: 0-4 min, hold at 10%; 4-10
min, 10-30%; 10-24 min, hold at 30%; 24-30 min 30-100%.
Tandem mass spectrometry (MS/MS) experiments using electron transfer dissociation (ETD)
were carried out on a Bruker HCTultra PTM Discovery System quadrupole ion trap mass
spectrometer. Samples were infused at a flow rate of 1 to 2 μL/min using a Cole Palmer syringe
pump (Vernon Hills, IL). ETD was performed using total reaction times of 50 to 200 ms and
low mass cutoffs ranging from m/z 30 to 200; these values were chosen to maximize the
dissociation efficiency. Accumulation times for the fluoranthene radical anion, which was used
as the ETD reagent, were optimized for each experiment but were typically between 3 ms and
5 ms.
RESULTS
MCO reactions of a single octarepeat, PrP(60-67)
Metal catalyzed oxidation (MCO) reactions of the octarepeat (PHGGGWGQ) were performed
to determine the oxidation pattern that should result when the octarepeat Cu binding site is
filled. MCO reactions of a 1:1 complex of Cu:Ac-PHGGGWGQ-NH2 result in the
incorporation of a single oxygen atom and the formation of two oxidized isomers. The oxidized
isomers can be separated by LC (Figure 2a inset), and the residues oxidized in each isomer can
be identified by MS/MS. The tandem mass spectrum (Figure 2a) of the first oxidized isomer,
corresponding to the first LC peak, shows unmodified b2, b3, b4, and b5 product ions that are
identical to the m/z ratios of the product ions in the tandem mass spectrum of the unoxidized
peptide (data not shown). Mass shifts of 16 Da for the a6, b6 and b7 product ions indicate that
Trp65 is the oxidized residue in this first isomer. In contrast, the tandem mass spectrum (Figure
2b) of the second isomer, corresponding to the third LC peak, shows oxidized product ions in
the series from b2 to b7, which confirms oxidation occurs at His61. We find that about 75% of
the peptide is oxidized at Hi61, while the remaining 25% is oxidized at Trp65. Oxidation of
the His and Trp residues is consistent with the model for Cu binding to the octarepeat (7) —
His is bound to Cu(II), while Trp is in close proximity to the Cu(II) binding site. Given its
expected proximity to Cu(II) and the ease with which it can be oxidized, Trp oxidation is
expected. No evidence is found for oxidation of any of the Gly residues that contribute
backbone amides to the Cu(II) binding site. This is not surprising as Gly lacks a side chain that
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can be oxidized. We have demonstrated previously that backbone cleavage can occur during
the MCO reactions of Cu-protein complexes (23), but no definitive evidence for this is found
in the current study. We conclude that His and Trp oxidation are MCO/MS indicators of Cu
binding to the octarepeat.
DEPC reactions of a single octarepeat, PrP(60-67)
DEPC reactions of the octarepeat-Cu(II) complex were also done to serve as a complementary
indicator of Cu binding to the octarepeat. DEPC can react selectively with His residues, but
this reaction is significantly slowed when His residues are bound to metal ions. As a control
experiment, DEPC was reacted with the octarepeat in the absence of Cu, and the mass spectrum
of the reaction products shows abundant ions corresponding to the DEPC-modified peptide
(Figure 3a). When DEPC reacts with the 1:1 Cu(II) complex of the peptide, the relative
abundance of modified peptide drops threefold, which is consistent with Cu binding inhibiting
the reaction of DEPC with His (Figure 3b). MS/MS of the ion corresponding to the DEPC
modified peak after reaction with either the metal-bound or metal-free peptide confirms that
modification occurs at His only (data not shown). This result indicates that Cu(II) simply drops
the reactivity of His toward DEPC. In this peptide sequence, other amino acids are not modified
by DEPC when Cu(II) is bound.
MCO reactions of PrP(89-98)
MCO reactions of the so-called fifth binding site, as modeled by WGQGGGTHNQ, were also
done to determine the oxidation pattern that should result when this binding site is filled. MCO
reactions of the 1:1 complex of Cu:Ac-WGQGGGTHNQ-NH2 lead to the incorporation of a
single oxygen atom and the formation of two oxidized isomers. The oxidized isomers can be
separated by LC (data not shown), and the modification sites can be confirmed by MS/MS in
a manner similar to that described above for the octarepeat. The MS/MS data indicate that
Trp89 is the oxidized residue in one of the isomers, and His96 is the oxidized residue in the
other isomer (data not shown). Oxidation at Trp89 accounts for 30% of the oxidized peptide,
while oxidation at His96 accounts for the remaining 70%. Previous EPR studies of Cu(II)’s
binding to this peptide indicate that His96 is one of the ligands (12), so oxidation of this residue
is expected. The previous EPR studies are not clear about the proximity of Trp89 to Cu(II),
but our MCO/MS results suggest that Trp may be close to Cu(II). Taken together, oxidation
of His96 and Trp89 are MCO/MS indicators of Cu(II) binding to PrP(89-98).
DEPC reactions of PrP(89-98)
Complementary information about the Cu(II) binding site of this peptide was obtained from
DEPC reactions of the Cu(II) complex of Ac-WGQGGGTHNQ-NH2. In contrast to the results
from the DEPC reaction of the complex of the octarepeat, the reactions of the Cu-bound form
of WGQGGGTHNQ lead to modification exclusively at Thr95, while DEPC reactions of the
non-Cu bound form of this peptide result in modification at His96 as indicated by MS/MS data
(not shown). Furthermore, in the presence of Cu, the peptide’s reactivity with DEPC drops by
about a factor 2. DEPC is known to react with other residues that have nucleophilic side chains
such as Tyr and Lys residues (30-32) and recently, the reactivity of DEPC with Thr residues
has also been reported (33). Overall, the reactivity of the Cu-bound form of the peptide is
reduced about 2-fold when compared to the non-Cu bound form. The observation that His
modification is replaced by Thr modification is a useful indicator of Cu binding to the GTH
binding site.
MCO reactions of PrP(23-28, 57-98)
With the appropriate indicators of Cu(II) binding to both PrP(60-67) and PrP(89-98)
determined, the MCO reactions of PrP(23-28, 57-98) were performed to explore its Cu(II)
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binding site(s) under different stoichiometric loadings of Cu(II). The mass spectra resulting
from the MCO reactions of complexes with stoichiometries ranging from 1:1 to 1:5 of PrP
(23-28, 57-98):Cu(II) indicate that singly, doubly, and triply oxidized ions are observed
(spectra not shown). As the Cu(II) concentration is increased the degree of oxidation, as
measured by the weighted average number of oxidative modifications, increases linearly. The
increased amount of oxidation is fully expected as the higher stoichiometries of Cu(II) cause
more peptide binding sites to be filled. To determine the amino acids that comprise the binding
sites at the different stoichiometric loadings, we performed MS/MS experiments only on the
singly-oxidized peptides. MS/MS experiments on the doubly- and triply-oxidized peptides
could lead to incorrect conclusions because the first oxidation event could disrupt the peptide
structure and cause a change in Cu(II) binding sites. In such a case, the second and third
oxidation events might not then be representative of the original Cu(II) binding mode.
Unlike the MS/MS experiments with PrP(60-67) and PrP(89-98), ETD rather than CID was
used to sequence PrP(23-28, 57-98) because ETD has been found to give more accurate and
readily interpretable spectra and more extensive sequence information for oxidized peptides,
especially large peptides (29). As an example of the type of data that is obtained after the MCO
reactions of PrP(23-28, 57-98), the ETD spectrum of the singly-oxidized peptide ion from the
MCO reaction of the 1:1 peptide:Cu complex is shown (Figure 4). This spectrum indicates that
all of the His residues in the peptide are oxidized but to varying extents (Figure 4 and Table
2). The oxidation extent of each His residue is determined by comparing the oxidation
percentages of the appropriate product ion in the ETD spectrum. For example, Figure 4b shows
expanded regions of the z2, z3, z10, and z14 product ions and, where applicable, their oxidized
versions. The percentage oxidized is obtained by dividing the ion abundance of the oxidized
product ion by the sum of the ion abundances of the oxidized and unoxidized product ions.
ETD product ion formation has been shown to be relatively insensitive to side chain
modifications (29), so we feel that the percent oxidation from the ETD spectra are reliable
indicators of the real degree of oxidation. From the data in Figure 4b, we conclude that the
oxidation extent for His96 is about 32%. We arrive at this value by subtracting the oxidation
percentage for the z2 ion (0%) from the oxidation percentage of the z3 ion (32%). In a similar
manner the oxidation percentage for Trp89 is determined to be 0% by subtracting the oxidation
percentage of the z6 (or z3) ion (32%) from the oxidation percentage of the z10 (32%) ion. As
a final example, the oxidation percentage of His85 is determined to be 12% by subtracting the
oxidation percentage of the z10 ion (32%) from the oxidation percentage of the z14 (44%) ion.
A similar type of accounting can be done for the other His residues oxidized in the 1:1 complex
and also can be done for the residues oxidized during the MCO reactions of the complexes
with higher stoichiometric loadings of Cu(II) (Scheme 2 and Table 2). In general, the errors in
the oxidation percentages range from ± 2 to ± 8%.
The data for the MCO reactions of the 1:1 and 1:2 complexes (Table 2) show that His residues
are oxidized but no Trp residues are oxidized. These results are noteworthy for three reasons.
First, the failure to observe oxidation of Trp residues probably indicates that only His residues
comprise the Cu(II) binding sites and that the coordinating ligands around Cu(II) are not
provided by a single octarepeat sequence in either the 1:1 or 1:2 complex. This is consistent
with previous studies in which low stoichiometric loadings of Cu resulted in complexes bound
only by His residues (13,14). Second, all of the His residues are found to be oxidized. Our
previous MCO/MS work has indicated that under appropriate reaction conditions Cu(II)
binding is necessary for oxidation to occur at a given residue (22-26). With this in mind,
oxidation of each His residues indicates that Cu can bind to each of the His residues in the 1:1
and 1:2 complexes. It is unlikely, however, that all 5 His residues are simultaneously bound
to Cu(II). Indeed, previous Cu(II)-binding studies on a PrP construct with 4 octarepeats
suggests that only three or four His residues are simultaneously bound at low stoichiometric
loadings of Cu(II) (13). Thus, in both the 1:1 and 1:2 complexes there are likely a mixture of
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binding modes that differ only in the His residues that are bound to Cu. Third, the trend in the
oxidation extent (i.e. His96 > His61, His69 > His77, His85) might suggest that 1:1 Cu:peptide
isoforms with His96 bound to Cu(II) are the most abundant, while the isoforms with His77
and His85 bound to Cu(II) are the least abundant.
An alternate explanation for the trend in oxidation extent is the possibility that different Cu
(II)-binding isoforms make different Cu(I) sites during the initial reduction step of the MCO
cycle (Scheme 1). Two-coordinate Cu(I) sites are known to be much less reactive with O2 than
three-coordinate Cu(I) sites (34). So, if the different isoforms are reduced to different Cu(I)
coordination numbers, then the trend in oxidation may not reflect Cu(II) occupancies but
instead might simply reflect different rates of ROS production. While we cannot rule out this
possibility in the current data set, in our previous MCO/MS work we observed that all residues
known to bind the Cu(II) center are oxidized to similar extents. We feel that this observation
would be unlikely if, upon reduction to Cu(I), the ligand set around the metal ever dropped to
two-coordinate. A more compelling reason why we do not favor the formation of Cu(I) sites
with different coordination numbers is the very good consistency of the MCO data with the
DEPC data (see below).
The data for the MCO/MS analysis of the higher stoichiometric loadings of Cu (1:3 to 1:5)
provide additional insight into Cu(II) binding to PrP(23-28, 57-98) (Scheme 2 and Table 2).
Two observations are noteworthy. First, in contrast to the 1:1 and 1:2 complexes, the MCO
reactions of the 1:3, 1:4, and 1:5 complexes result in the oxidation of Trp residues. These data
indicate that all the octarepeat binding sites begin to be filled at stoichiometries of 1:3 and
higher, whereas they are not filled at lower stoichiometries. This observation is also consistent
with the recent report by Millhauser and co-workers (13), which indicates a different
coordination environment at higher stoichiometric loadings of Cu(II). There is not a clear
preference for which octarepeat segment is filled first. Second, the 1:3, 1:4, and 1:5 binding
stoichiometries result in essentially the same trend in oxidation extent as the 1:1 and 1:2
stoichiometries: His96 > His61, His69 > His77, His85. This trend suggests the importance of
His96 binding site at all stoichiometric loadings. As an aside, the accuracy of the MCO method
is evidenced by the fact that Trp57 is not oxidized even at higher Cu loadings (Scheme 1 and
Table 2). Trp57 is not part of any octarepeat, so it is not expected to be oxidized, and indeed
this is what is observed.
DEPC reactions of PrP(23-28, 57-98)
As a complement to the MCO/MS data, DEPC modification reactions on PrP(23-28, 57-98)
with different stoichiometric loadings of Cu were also examined. Mass spectra obtained after
DEPC reactions of Cu bound and non-Cu bound PrP(23-28, 57-98) indicate that the presence
of Cu reduces the reactivity of DEPC with the peptide in a manner similar to that described
above for the octarepeat (spectra not shown). Furthermore, the extent of modification decreases
in an approximately linear fashion as the stoichiometry of Cu(II) increases. The ETD spectrum
obtained after the DEPC reaction of the Cu(II)-free form of PrP(23-28, 57-98) indicates that
all five His residues in the peptide are modified but to varying extents (Scheme 3 and Table
3). Just as in the MCO/MS experiments, MS/MS was performed only on the singly-modified
peptide ions to avoid potentially misleading results due to disruption of the peptide structure
upon modification. As an example, the ETD spectrum of the singly-modified peptide ion
obtained after the DEPC reaction of the 1:1 complex is shown in Figure 5. The modification
extent of each residue is determined by comparing the modification percentages of the
appropriate product ion in the ETD spectrum. For example, Figure 5b shows expanded regions
of the z3, z4, c8, and c16 product ions and, where applicable, their modified versions. From the
data in Figure 5b, we conclude that there is no modification at His96, but modification of Thr95
is observed at 9%. We arrive at this value using the same accounting method for determining
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the degree of oxidation, as discussed in the previous section. A similar type of accounting can
be done for the other residues modified in the 1:1 complex and also can be done for the residues
modified during the DEPC reactions of the complexes with higher stoichiometric loadings of
Cu(II) (Scheme 3 and Table 3). For the 1:1 complex, the results indicate that His96 is the least
reactive, His85 is the most reactive, and His61, His69, and His77 have similar reactivities. If
one recalls that lower DEPC reactivity corresponds to Cu(II) binding, then it is clear that this
reactivity trend is qualitatively similar to that observed in the MCO/MS experiments. The
clearest conclusion from the two data sets (i.e. MCO and DEPC) for the 1:1 complex is that
His96 is the dominant Cu(II) binding site.
When the data from the DEPC reactions of all the complexes with different stoichiometric
loadings of Cu are considered as a whole, three observations are noteworthy. First, the failure
of His96 to react with DEPC whenever Cu is present suggests that this residue is a Cu(II)
binding site in all of the complexes, at both low and high stoichiometric loadings of Cu. Second,
His77 is the last His site filled as the Cu(II) concentration is increased. At stoichiometric
loadings of 1:2, 1:3, and 1:4, this residue remains the most reactive, indicating that this residue
is less likely to be bound by Cu at these stoichiometric loadings than the other His residues.
This observation is very consistent with the MCO/MS data, which shows this residue to be the
least reactive. Third, all the His residues, and probably all the octarepeats, are filled at a
stoichiometric loading of 1:5 because none of the His residues react with DEPC under this
condition.
DISCUSSION
Collectively, the data presented here demonstrate that Cu(II) ions are bound by PrP’s metal
binding domain using different coordination modes that are a function of Cu(II) concentration.
Since the Cu(II)-coordination spheres are known for the case where the metal binding domain
is fully saturated, we were able to develop MCO/MS and DEPC/MS indicators for these binding
modes. For a single octarepeat, oxidation of both the His and Trp residues is indicative of the
coordination sphere observed in the X-ray structure of the HGGGW-Cu(II) complex (7) (Figure
6a). This involves equatorial coordination of Cu(II) by the His imidazole nitrogen,
deprotonated amide nitrogens from the following two Gly residues and the carbonyl oxygen
of the second Gly. The Trp indole ring is held in close proximity to the Cu(II) center, possibly
via a hydrogen bonding interaction to an axially bound water molecule. A complementary
indicator is the protection of His from DEPC modification when it binds Cu(II), although this
is less structurally informative than the MCO/MS indicator.
In a similar manner, oxidation of the His and Trp residues in the Cu(II):Ac-WGQGGGTHNQ-
NH2 complex is indicative of the coordination sphere revealed by numerous spectroscopic
studies (12,35,36) (Figure 6b). Here, Cu(II) is coordinated by deprotonated amide nitrogens
from the Gly, Thr and His residues as well as the imidazole ring of His. Interestingly, the DEPC
modification is much more informative for this site as His is protected from modification, but
the Thr side-chain becomes readily functionalized. When the PrP(23-28, 57-98) peptide was
fully Cu(II)-loaded (i.e. exposed to 5 eq. of Cu(II)), both MCO/MS and DEPC/MS indicators
were observed. Thus, we conclude these methods are reliable reporters of the local Cu(II)-
coordination spheres.
The MCO/MS and DEPC/MS monitored Cu(II) titration of PrP(23-28, 57-98) reveal the
existence of coordination mode(s) different than those exhibited by a single octarepeat (PrP
60-67) or single ‘5th binding site’ (PrP 89-98). At 1:1 and 1:2 PrP(23-28, 57-98):Cu(II) ratios,
all of the His residues were subject to oxidation, although to varying extents, whereas no Trp
residues were oxidized. In addition, all His residues were afforded protection from DEPC
modification, again to varying extents, plus Thr95 became increasingly DEPC modified.
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Together, these data indicate that the coordination spheres exhibited by the octarepeat-Cu(II)
or WGQGGGTHNQ-Cu(II) complexes are not populated in PrP(23-28, 57-98) at these Cu(II)
stoichiometries. The simplest explanation for these observations is the existence of a binding
mode or modes that involve multiple His coordination of a single Cu(II) ion. Further, the
different extents to which the His residues are oxidized or protected from DEPC modification
suggest that isomers of this binding mode exist.
Other research groups have found evidence for the coordination of a single Cu(II) ion by
multiple His imidazoles at low peptide:Cu(II) ratios, and our findings here support this. Using
peptide models of only the octarepeat region (residues 57-91) and a suite of EPR techniques,
Chattopadhyay et al. propose a coordination sphere where Cu(II) is equatorially ligated by
three or four His imidazoles (13). Wells et al. performed a variety of spectroscopic studies on
an octarepeat peptide spanning residues 57-91 plus a construct encompassing residues 91-115
(14). Their findings corroborate those of Chattopadhyay et al. with regard to multiple His
binding by the octarepeat region, and they highlight the existence of two binding sites C-
terminal to this region. They also examined recombinant, full length human PrP (residues
23-231) at pH 5.5 by 2D NMR and found that six His residues (the four from the octarepeat
region, His96 and His111) coordinated two Cu(II) ions (19). The lower pH conditions used in
their study favor formation of the multiple His coordination sphere at low Cu(II) occupancy.
Based on their observation that the signal heights for all six N-terminal His residues (i.e. those
contained between residues 57-111) plus the N-terminal amine were significantly reduced upon
the addition of 1 equivalent of Cu(II), they conclude that at least seven functional groups
contribute to coordinating a single Cu(II) ion. Since it is unfeasible that this number of ligands
would simultaneously coordinate a single Cu(II), they propose there must be an ensemble of
different coordination spheres that involve different combinations of these ligands, yet have
comparable stabilities.
Our data are clear on the fact that His96 is a dominant Cu(II) binding ligand in the PrP(23-28,
57-98) peptide. At every PrP:Cu(II) ratio, i.e. from 1:1 to 1:5, His96 was preferentially oxidized
and, conversely, preferentially provided protection from DEPC modification. This piece of
information allows us to put an upper limit on the number of possible isomers that can exists
at 1:1 PrP(23-28, 57-98):Cu(II) ratios. If it is assumed that Cu(II) is bound by four His
imidazoles then there are four possible isomers, and if it is assumed that Cu(II) is bound by
three His imidazoles then there are seven possible isomers. Currently, our measurements are
done on the mixture of these isomers, but we cannot definitely comment on exactly how many
isomers are present.
In agreement with the work by Millhauser and coworkers, plus Wells et al., our data show that
the individual octarepeat binding sites begin to be filled at stoichiometries of 1:3 and higher
as indicated by the oxidation of the Trp residues. There is not a clear preference for the order
in which the octarepeat segments load with Cu(II), although the His77 octarepeat appears to
saturate last.
As mentioned above, Wells at al. also indicate that His111 is involved in Cu(II) coordination
as one of several His ligands. Klewpatinond et al. instead argue that the residues spanning
107-111, TNMKH (human sequence), constitute a high affinity binding site where three
deprotonated amides and the His111 side chain coordinate the Cu(II) ion (15). Since our peptide
only extends to residue 98, and thus lacks His111 plus the adjacent residues, we are unable to
comment on this in much depth. However, given that the binding site at His96 (GTH) appears
to be of higher affinity than that centered at His111 (TNMKH) (12,15) and the fact that at low
Cu(II) stoichiometries His96 is involved in a multiple His binding mode, it is likely that His111
would behave in a similar manner as suggested by the NMR study by Wells et al. Nevertheless,
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it is clear that in order to obtain a complete picture of the Cu(II) binding process, systems must
include the region encompassing His111.
The ability of PrP to bind Cu(II) using multiple His ligands, as observed at low Cu(II):PrP
stoichiometries, is interesting for a number of reasons. Firstly, this is the highest affinity binding
mode and thus very likely populated under physiological conditions where the Cu(II)
concentration is low and there are numerous competitors. Secondly, as Cu(II) binding by PrP
is very pH sensitive this mode may predominate at lower pH values (e.g. 5.5) and thus might
also occur in the acidic environment of the endosome. Thirdly, as suggested by others, the
participation of several His residues in the binding of a single Cu(II) offers a potential
mechanism by which PrP molecules can self-associate (19,37,38). In such a self-association
mode, a single Cu(II) ion would be coordinated by His residues from at least two different PrP
molecules. Lastly, a multiple His binding mode will clearly cause compaction of the 60-98
region (possibly up to 111), as the His residues are spread throughout it, and thus a significant
change in the shape of the protein. It will most certainly change the orientation of the N-
terminus with respect to the C-terminus.
It is curious that nature would design a copper-binding protein with a Cu(II) ion held in an
ensemble of different coordination spheres even though the coordinating species are all
essentially equivalent, i.e. His imidazoles. This leads us to speculate that 1:1 PrP:Cu complex
may bear some of the hallmarks of a ‘natively unfolded’ protein. Two major features of this
class of proteins include the ability to bind several different targets and precise thermodynamic
control over binding processes (39,40). No matter what conformation apo-PrP exists in before
binding, it should readily be able to coordinate a Cu(II) ion without needing significant energy
to reorganize. Additionally, if there is exchange between the several ‘degenerate’ Cu-binding
modes, the PrP:Cu complex may possess enough ‘plasticity’ to readily accept additional Cu
(II) ions. If PrP had a single, very stable binding site then there might be a significant barrier
for the protein to change its conformation in order to accept additional copper. Consideration
of these findings makes it difficult to envision an enzymatic function for PrP, as the different
isomeric Cu(II) binding modes would be expected to reduce the specificity of substrate binding.
Abbreviations
PrP, prion protein
PrPC, cellular isoform of PrP
PrP(23-28, 57-98), residues 23 through 28 and 57 through 98 of PrP
MCO, metal catalyzed oxidation
MS, mass spectrometry
MS/MS, tandem mass spectrometry
DEPC, diethyl pyrocarbonate
ETD, electron transfer dissociation
CID, collision-induced dissociation
LC, liquid chromatography
NMR, nuclear magnetic resonance.
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Scheme 1.
Generation of reactive oxygen species during MCO reactions.
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Scheme 2.
Oxidation percentages obtained after ETD analysis of MCO reacted PrP(23-28, 57-98) with
various copper stoichiometries.
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Scheme 3.
Oxidation percentages obtained after ETD analysis of DEPC reacted PrP(23-28, 57-98) with
various copper stoichiometries.
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Figure 1.
Sequence information and structural details for human PrP. The metal binding region resides
in the flexible N-terminal domain and the five main Cu(II) binding sites are located in the
region of residues 60-96. The underlined residues constitute binding sites under Cu(II)-
saturating conditions.
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Figure 2.
CID spectra of the oxidized single octarepeat PrP(60-67) peptide. (a) Product ion spectrum of
the Trp65-oxidized PrP(60-67) peptide (M+O+H)+. (b) Product ion spectrum of the His61-
oxidized PrP(60-67) peptide (M+O+H)+. The ions labeled with asterisks are oxidized product
ions. The individual oxidized Trp65 and oxidized His61 were obtained by separating them by
HPLC. Inset figure is the HPLC chromatogram of oxidized sample of PrP(60-67).
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Figure 3.
Mass spectrum of the DEPC modified PrP(60-67) peptide after reaction (a) in the absence of
Cu and (b) in the presence of Cu. A mass increase of +72 Da is observed upon reaction with
DEPC.
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Figure 4.
(a) ETD spectrum of the singly-oxidized peptide ion from the MCO reaction of the 1:1
peptide:Cu complex. (b) Expanded regions of the z2, z3, z10, and z14 product ions and their
oxidized versions. The ions labeled with asterisks are oxidized product ions.
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Figure 5.
(a) ETD spectrum of the singly-modified peptide ion obtained after the DEPC reaction of the
1:1 peptide:Cu complex. (b) Expanded regions of the z3, z4, c8, and c16 product ions and their
modified versions. The ions labeled with asterisks are DEPC-modified product ions.
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Figure 6.
(a) The structure of a single octarepeat binding site was determined from crystallographic and
spectroscopic data. The metal catalyzed oxidation of this site leads to oxidation of both the His
and Trp residues. (b) The coordination sphere for the GTH site, residues 94-96, is a model
based on spectroscopic data. The metal catalyzed oxidation of this site leads to oxidation of
the His residue.
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Table 1
PrP-Derived Peptide Sequences
PrP(60-67) Ac-PHGGGWGQ-NH2
PrP(89-98) Ac-WGQGGGTHNQ-NH2
PrP(23-28,57-98) Ac-KKRPKPWGQ(PHGGGWGQ)4GGGTHNQ-NH2
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